New hope for stomach cancer patients with abdominal spread: targeted drug combo enters trial
NCT ID NCT07556640
First seen Apr 30, 2026 · Last updated May 05, 2026 · Updated 1 time
Summary
This study tests a combination of drugs (LM-302, S-1, and paclitaxel given into the abdomen, with or without cadonilimab) in people with a specific type of advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this treatment helps patients live longer. About 74 adults whose cancer cells have a protein called Claudin 18.2 will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Huangpu District, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.